NECAB1: A Potential Drug Target and Biomarker for EF-Hand Calcium Binding Protein 1

Target Name: NECAB1

NCBI ID: G64168

NECAB1

NECAB1: A Potential Drug Target and Biomarker for EF-Hand Calcium Binding Protein 1

Introduction

Calcium homeostasis is a crucial aspect of many biological processes, including muscle contractions, nerve function, and brain activity. The protein EF-hand calcium binding protein 1 (NECAB1) is a key regulator of calcium homeostasis, and its dysfunction has been implicated in numerous diseases, including muscular dystrophy, neurodegenerative diseases, and chronic pain. As such, NECAB1 has emerged as a promising drug target and biomarker for a variety of diseases.

Overview of NECAB1

NECAB1 is a 25 kDa protein that is expressed in most tissues and cells. It is a member of the EF-hand family of proteins, which are known for their ability to bind to calcium ions. NECAB1 functions as a calcium ion regulator, participating in the regulation of intracellular calcium levels. This protein has been shown to play a crucial role in muscle function, nerve activity, and brain activity.

Dysfunction of NECAB1

NECAB1 dysfunction has been implicated in a number of diseases, including muscular dystrophy, neurodegenerative diseases, and chronic pain. For example, studies have shown that individuals with dystrophied muscles have lower levels of NECAB1 than healthy individuals. Additionally, NECAB1 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Potential Therapeutic Applications

Given the promising role of NECAB1 in numerous diseases, there is significant interest in using NECAB1 as a drug target or biomarker for a variety of conditions. One potential approach to targeting NECAB1 is to use small molecules that can modulate its activity. For example, a number of studies have shown that inhibitors of NECAB1 can alleviate muscle weakness and dysfunction in dystrophied muscles. Additionally, NECAB1 has been shown to play a role in pain signaling, and therefore, inhibitors of NECAB1 have been shown to be effective in reducing pain in a variety of models.

Another potential approach to targeting NECAB1 is to use antibodies that can specifically recognize and target the protein. This approach has been shown to be effective in reducing muscle weakness and dysfunction in dystrophied muscles, and has been used to treat a variety of diseases, including muscular dystrophy and cancer.

Biomarker Applications

NECAB1 has also been shown to be a potential biomarker for a variety of diseases. For example, NECAB1 levels have been shown to be reduced in individuals with dystrophied muscles, and this reduction has been associated with muscle weakness and dysfunction. Additionally, NECAB1 has been shown to be involved in pain signaling, and its levels have been shown to be increased in individuals with pain.

Conclusion

In conclusion, NECAB1 is a protein that plays a crucial role in calcium homeostasis and has been implicated in a variety of diseases. Its dysfunction has been implicated in muscle weakness, nerve activity, and brain activity. As such, NECAB1 has emerged as a promising drug target and biomarker for a variety of diseases. The use of small molecules and antibodies to modulate NECAB1 activity has the potential to lead to new treatments for a variety of conditions. Further research is needed to fully understand the role of NECAB1 in disease and to develop effective treatments.

Protein Name: N-terminal EF-hand Calcium Binding Protein 1

The "NECAB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NECAB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets